QC
SUPN icon

Quadrature Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Quadrature Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,501
Closed -$594K – 2036
2026
Q1 		$594K Buy
11,501
+6,116
+114% +$311K 0.01% 733
2025
Q4 		$268K Buy
+5,385
New +$262K ﹤0.01% 884
2025
Q3 		– Sell
-7,850
Closed -$247K – 1472
2025
Q2 		$247K Buy
+7,850
New +$252K ﹤0.01% 746

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Quadrature Capital's SUPN Position: Q2 2026 in Review

Quadrature Capital sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 11,501 shares — an estimated $594K sold.

Quadrature Capital first reported a position in SUPN in Q2 2025 and held it in 3 quarters. The position peaked at $594K in Q1 2026. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Quadrature Capital reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Quadrature Capital sold 11,501 Supernus Pharmaceuticals shares in Q2 2026, an estimated $594K.
  • Quadrature Capital first reported a position in Supernus Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Quadrature Capital's Supernus Pharmaceuticals position peaked at $594K in Q1 2026.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.